[Skip to Navigation]
Sign In
Comment & Response
August 15, 2019

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer—In Reply

Author Affiliations
  • 1Ospedale Policlinico San Martino Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy
JAMA Oncol. 2019;5(10):1512. doi:10.1001/jamaoncol.2019.2991

In Reply Raghav and Strickler raise 3 major questions in their response to our article1: (1) was the survival effect in the HERACLES study determined by anti-EGFR or by chemotherapy? (2) was ERBB2 amplification (referred to as “HER2-amplification” in our article, but herein referred to as “ERBB2-amplification”) high enough in those patients deriving a benefit from anti-EGFR therapy? (3) is ctDNA analysis reliable when testing for ERBB2 amplification?

Add or change institution